Randomized trial of a fixed combination (KanJang )
... The clinical efficacy of KanJangs oral solution, a fixed combination of standardised extracts of Echinacea purpurea, Adhatoda vasica and Eleutherococcus senticosus, was compared with the combined extracts of Echinacea purpurea and Eleutherococcus senticosus alone (Echinacea mixture) in a controlled, d ...
... The clinical efficacy of KanJangs oral solution, a fixed combination of standardised extracts of Echinacea purpurea, Adhatoda vasica and Eleutherococcus senticosus, was compared with the combined extracts of Echinacea purpurea and Eleutherococcus senticosus alone (Echinacea mixture) in a controlled, d ...
united states securities and exchange commission - corporate
... Cerecor Announces Acquisition of TARP-γ8-AMPA Receptor Antagonist (CERC-611) from Lilly Phase 1 development for epilepsy expected to commence in 2017 BALTIMORE--(BUSINESS WIRE)--September 26, 2016-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make ...
... Cerecor Announces Acquisition of TARP-γ8-AMPA Receptor Antagonist (CERC-611) from Lilly Phase 1 development for epilepsy expected to commence in 2017 BALTIMORE--(BUSINESS WIRE)--September 26, 2016-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make ...
Harvard-MIT Division of Health Sciences and Technology
... 1. Dissolution of lipid-soluble drugs in adipose tissue 2. Binding of drugs to intracellular sites 3. Plasma protein binding; many drugs reversibly bind to albumin, α1-acid glycoprotein or other proteins in plasma; extent of binding dependent on affinity, number of binding sites, and drug concentrat ...
... 1. Dissolution of lipid-soluble drugs in adipose tissue 2. Binding of drugs to intracellular sites 3. Plasma protein binding; many drugs reversibly bind to albumin, α1-acid glycoprotein or other proteins in plasma; extent of binding dependent on affinity, number of binding sites, and drug concentrat ...
Progression-free survival
... Because the protocols did not distinguish among subtypes, the analyses reported in this study were also performed without regard to subtype. Patients could be entered in more than one protocol and were included for each protocol in which they were enrolled. Analyses were repeated including these pat ...
... Because the protocols did not distinguish among subtypes, the analyses reported in this study were also performed without regard to subtype. Patients could be entered in more than one protocol and were included for each protocol in which they were enrolled. Analyses were repeated including these pat ...
CLIs OMS I Fall 2013 - lshstudentresources.com
... • This test is performed on patients experiencing chest pain to determine if the pain is caused by cardiac ischemia. It is a specific indicator of cardiac muscle injury. • Cardiac troponins are biochemical markers for cardiac disease and can actually be used in patients with unstable angina to deter ...
... • This test is performed on patients experiencing chest pain to determine if the pain is caused by cardiac ischemia. It is a specific indicator of cardiac muscle injury. • Cardiac troponins are biochemical markers for cardiac disease and can actually be used in patients with unstable angina to deter ...
Targeting cell signaling pathways for drug discovery
... In this age of targeted therapy, the failure of most current drug-discovery efforts to yield safe, effective, and inexpensive drugs has generated widespread concern. Successful drug development has been stymied by a general focus on target selection rather than clinical safety and efficacy. The very ...
... In this age of targeted therapy, the failure of most current drug-discovery efforts to yield safe, effective, and inexpensive drugs has generated widespread concern. Successful drug development has been stymied by a general focus on target selection rather than clinical safety and efficacy. The very ...
Supplemental Table 2. Dose regimens of polymyxins used in the
... Colistin can be used IM at the same doses as IV ...
... Colistin can be used IM at the same doses as IV ...
-click here for handouts (full page)
... W. Huffman-researched the interaction between drugs and brain receptors. Worked on ligands for the cannabinoid receptors. The chemical compounds Huffman developed have been made into synthetic marijuana that is marketed as "Spice," "K-2," "Skunk" and similar products. ...
... W. Huffman-researched the interaction between drugs and brain receptors. Worked on ligands for the cannabinoid receptors. The chemical compounds Huffman developed have been made into synthetic marijuana that is marketed as "Spice," "K-2," "Skunk" and similar products. ...
Durogesic Article-30 referral
... indicated in section 4.1 of the proposed harmonised SmPC, and also present in the majority of SmPCs. The proposed wording has been developed to align the populations evaluated in clinical studies and to maintain alignment between the indications for both adult and paediatric patients. Section 4.2 – ...
... indicated in section 4.1 of the proposed harmonised SmPC, and also present in the majority of SmPCs. The proposed wording has been developed to align the populations evaluated in clinical studies and to maintain alignment between the indications for both adult and paediatric patients. Section 4.2 – ...
Product Information – Australia Chemmart Bisoprolol Tablets Page 1
... Abrupt withdrawal: The cessation of therapy with bisoprolol should not be done abruptly unless clearly indicated. Care should be taken if β-blockers have to be discontinued abruptly in patients, particularly in patients with coronary artery disease. Severe exacerbation of angina and precipitation of ...
... Abrupt withdrawal: The cessation of therapy with bisoprolol should not be done abruptly unless clearly indicated. Care should be taken if β-blockers have to be discontinued abruptly in patients, particularly in patients with coronary artery disease. Severe exacerbation of angina and precipitation of ...
Drugs:Uses and Abuses— Stimulants
... substances that enter from outside the body and against some cancer cells that arise within. ● Understand that the nervous system works by electrochemical signals in the nerves and from one nerve to the next. The hormonal system exerts its influences by chemicals that circulate in the blood. These t ...
... substances that enter from outside the body and against some cancer cells that arise within. ● Understand that the nervous system works by electrochemical signals in the nerves and from one nerve to the next. The hormonal system exerts its influences by chemicals that circulate in the blood. These t ...
HYPERTENSION ABC & Update
... Ask patient to rate (1 to 10) his or her chance of staying on treatment Inform patient about recommended treatment and provide specific written information about the role of lifestyle, including diet, physical activity, dietary supplements, and alcohol intake; use standard brochures when available E ...
... Ask patient to rate (1 to 10) his or her chance of staying on treatment Inform patient about recommended treatment and provide specific written information about the role of lifestyle, including diet, physical activity, dietary supplements, and alcohol intake; use standard brochures when available E ...
QA50_8_Hypersalivationgeneral
... However, the published data available are mainly limited to the use of oral glycopyrronium in children and young adults with neurodevelopmental disabilities (4,17-21). In one small study in adult patients with Parkinson’s disease, 39% responded to treatment with oral glycopyrronium (22). The authors ...
... However, the published data available are mainly limited to the use of oral glycopyrronium in children and young adults with neurodevelopmental disabilities (4,17-21). In one small study in adult patients with Parkinson’s disease, 39% responded to treatment with oral glycopyrronium (22). The authors ...
PRODUCT MONOGRAPH ELAVIL® Amitriptyline Hydrochloride
... reactions in infants from amitriptyline, a decision should be made whether to discontinue nursing or discontinue the drug. Children: In view of the lack of experience with the use of this drug in the treatment of depression in children, amitriptyline is not recommended for depressed patients under 1 ...
... reactions in infants from amitriptyline, a decision should be made whether to discontinue nursing or discontinue the drug. Children: In view of the lack of experience with the use of this drug in the treatment of depression in children, amitriptyline is not recommended for depressed patients under 1 ...
Drug Therapy of Parkinsonism
... bromocriptine and pergolide than with levodopa. * Like levodopa, brompcriptine and pergolide are contraindicated in patients with history of psychosis. * Pramipexole: Recently introduced dopamine receptor agonists; they are not ergot derivatives. # They are presently considered to be first-line drug ...
... bromocriptine and pergolide than with levodopa. * Like levodopa, brompcriptine and pergolide are contraindicated in patients with history of psychosis. * Pramipexole: Recently introduced dopamine receptor agonists; they are not ergot derivatives. # They are presently considered to be first-line drug ...
Awakenings (1990): The epidemic of children who fell asleep
... Leonard still cannot sleep, almost immobilised by so many tics (sudden, rapid, nonrhythmic, stereotyped, involuntary movements) or exhaustion, and realises that Sayer is the only one who can help him. The other patients become alarmed at Leonard’s reaction to the drug and fear the same luck: And if ...
... Leonard still cannot sleep, almost immobilised by so many tics (sudden, rapid, nonrhythmic, stereotyped, involuntary movements) or exhaustion, and realises that Sayer is the only one who can help him. The other patients become alarmed at Leonard’s reaction to the drug and fear the same luck: And if ...
Elimination
... Many drugs are either weak bases or acids and therefore the pH of the filtrate can greatly influence the extent of tubular re-absorption for many drugs. When urine is acidic weak acid drugs tend to be reabsorbed (unionized). Alternatively when urine is more alkaline, weak bases are more extensively ...
... Many drugs are either weak bases or acids and therefore the pH of the filtrate can greatly influence the extent of tubular re-absorption for many drugs. When urine is acidic weak acid drugs tend to be reabsorbed (unionized). Alternatively when urine is more alkaline, weak bases are more extensively ...
Biosketch - UNC School of Medicine
... propose the first mechanism to explain biased receptor signaling (this mechanism is still considered to explain the effect and recent 19F-NMR data directly support the mechanism). The stabilization of unique receptor conformations by ligands that go then go on to differentially active cellular funct ...
... propose the first mechanism to explain biased receptor signaling (this mechanism is still considered to explain the effect and recent 19F-NMR data directly support the mechanism). The stabilization of unique receptor conformations by ligands that go then go on to differentially active cellular funct ...
CLOSPORIL® 0.1% - Laboratorios Poen
... administration of CLOSPORIL ® 0.1% to human beings twice a day for 12 months. All sample values were lower than the limit of quantification (0.1 ng/mL). No quantifiable drug accumulations were observed throughout the 12 month treatment with CLOSPORIL ® 0.1% ophthalmic solution. When a single ocular ...
... administration of CLOSPORIL ® 0.1% to human beings twice a day for 12 months. All sample values were lower than the limit of quantification (0.1 ng/mL). No quantifiable drug accumulations were observed throughout the 12 month treatment with CLOSPORIL ® 0.1% ophthalmic solution. When a single ocular ...
Sinarest Levo Syrup
... plasma half-life is in the range of 2 - 3 hours. Distribution: The volume of distribution is large (200 to 500 litres). Penetration of the brain and excretion in breast milk appear to be minimal. Phenylephrine does not cross the placenta. The extent of protein binding is unknown. Metabolism: Phenyle ...
... plasma half-life is in the range of 2 - 3 hours. Distribution: The volume of distribution is large (200 to 500 litres). Penetration of the brain and excretion in breast milk appear to be minimal. Phenylephrine does not cross the placenta. The extent of protein binding is unknown. Metabolism: Phenyle ...
IRB Terms Glossary
... Causal Hypothesis: A statement hypothesizing that the independent variable affects the dependent variable in some way. Causal Relationship: A relationship where an independent variable affects a dependent variable in some way. Children: Persons who have not yet attained the legal age for consent to ...
... Causal Hypothesis: A statement hypothesizing that the independent variable affects the dependent variable in some way. Causal Relationship: A relationship where an independent variable affects a dependent variable in some way. Children: Persons who have not yet attained the legal age for consent to ...
this PDF file
... no known medical use and a high potential for abuse (DEA, 2011). As a result, nearly all research on psychedelics was placed on hold until the early 1990s, when several investigators received approval from the Food and Drug Administration (FDA) to conduct carefully designed research trials. In 1995, ...
... no known medical use and a high potential for abuse (DEA, 2011). As a result, nearly all research on psychedelics was placed on hold until the early 1990s, when several investigators received approval from the Food and Drug Administration (FDA) to conduct carefully designed research trials. In 1995, ...
Introduction and Philosophy
... million persons ages 12 or older who used prescription type psychotherapeutic drugs non-medically in the past month. There were 180,000 persons who used heroin for the first time in 2009, which spiked from the average annual number from previous years. Estimates from 2002 to 2008 ranged from 91,000 ...
... million persons ages 12 or older who used prescription type psychotherapeutic drugs non-medically in the past month. There were 180,000 persons who used heroin for the first time in 2009, which spiked from the average annual number from previous years. Estimates from 2002 to 2008 ranged from 91,000 ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.